Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02927951 · ClinicalTrials.gov registry record · Phase 3
The Effect of Pregabalin on Pain Related to Walking in Patients With Diabetic Peripheral Neuropathy
A Phase 3 study of Diabetic Peripheral Neuropathy and Nerve Pain, sponsored by Eastern Virginia Medical School.
- Completed
- Registry status
- Phase 3
- Development phase
- 44
- Enrollment target
- 2
- Study locations
NCT02927951: Completed Phase 3 study of Diabetic Peripheral Neuropathy and Nerve Pain, sponsored by Eastern Virginia Medical School.
NCT02927951 is a Phase 3 study of Diabetic Peripheral Neuropathy and Nerve Pain that has completed, run by Eastern Virginia Medical School. The registered enrollment target is 44 participants, below the 126-participant average among 17 other Diabetic Peripheral Neuropathy trials with a reported enrollment target (65% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02927951, a Phase 3 study of Diabetic Peripheral Neuropathy and Nerve Pain, has completed, sponsored by Eastern Virginia Medical School.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 44 participants
- Enrollment target
- 2
- Study locations
Study Summary
The hypothesis of this study is that pregabalin, 150 mg bid, will reduce general daytime pain in patients diagnosed with diabetic peripheral neuropathy and that it will also reduce the level of pain associated with walking. Consequently, it is hypothesized that the reduction in pain will result in an increase in the amount of walking they do during the day, improvements in their gait, balance, risk of falls and sleep patterns.
Primary Outcome
The falls risk will also be ascertained using the long-form Physiological Profile Assessment. The Physiological Profile Assessment has been validated in prospective studies of falls in both community and institutional settings, and predicts those at increased risk of falling with 75-79% accuracy. The Physiological Profile Assessment includes tests of vision (edge contrast sensitivity, high/low contrast visual acuity, depth perception), sensation (ankle touch sensitivity, leg proprioception), leg
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Pregabalin
Study Locations (2)
Virginia
- Eastern Virgnia Medical School, Strelitz Diabetes Center - Norfolk
- Strelitz Diabetes Center - Norfolk
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2011-01 |
| Est. Completion | 2013-12 |
| Phase | Phase 3 |
What the finished NCT02927951 record still lists
NCT02927951 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 44 participants, a relatively small participant target, below the 126-participant average among 17 other Diabetic Peripheral Neuropathy trials with a reported enrollment target (65% lower).
The record links to 2 conditions, with Diabetic Peripheral Neuropathy appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02927951 reports a single indexed study location in Virginia.
Frequently Asked Questions
What is clinical trial NCT02927951 about?
NCT02927951 is a clinical study titled "The Effect of Pregabalin on Pain Related to Walking in Patients With Diabetic Peripheral Neuropathy". The hypothesis of this study is that pregabalin, 150 mg bid, will reduce general daytime pain in patients diagnosed with diabetic peripheral neuropathy and that it will also reduce the level of pain associated with walking. Consequently, it is hypothesized that the reduction in pain will result in a...
What is the current status of trial NCT02927951?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 44 participants. The study started on 2011-01. Estimated completion is 2013-12.
What conditions does trial NCT02927951 study?
This clinical trial studies the following conditions: Diabetic Peripheral Neuropathy, Nerve Pain.
What interventions are being tested in trial NCT02927951?
The interventions under investigation include: Placebo (DRUG), Pregabalin (DRUG).
Who is sponsoring clinical trial NCT02927951?
This trial is sponsored by Eastern Virginia Medical School, which has 36 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02927951 being conducted?
This trial has 2 study locations across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetic Peripheral Neuropathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02927951's enrollment target sits among peer trials
44 12th of 17 higher than 4 of 17 other Diabetic Peripheral Neuropathy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diabetic Peripheral Neuropathy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate the Efficacy, Safety, and Tolerability of Tapentadol ER Compared With Placebo in Patients With Chronic, Painful Diabetic Peripheral Neuropathy
COMPLETED · Phase 3
-
Walking Function in Diabetic Peripheral Neuropathy
RECRUITING · NA
-
Spinal Cord Stimulation and Small Fiber Peripheral Neuropathy
RECRUITING · NA
-
Innovative Multi-Variable Biofeedback for Improving Gait Performance in Individuals With Diabetic Peripheral Neuropathy
RECRUITING · NA
-
Functional and Neuroprotective Effects of Restoring Lower Limb Sensation After Diabetic Peripheral Neuropathy
RECRUITING · NA
-
Balance Control and Recovery in Diabetes Peripheral Neuropathy
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02323945 · 44 participants · NA
Effects of Breathing Mild Bouts of Low Oxygen on Limb Mobility After Spinal Injury
- NCT03093909 · 44 participants · Phase 1
Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases
- NCT03104491 · 44 participants · Phase 1
Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia
- NCT03781765 · 44 participants · Phase 4
Stimulant vs. Non-stimulant Treatments and Reward Processing in Drug-naive Youth at SUD Risk
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia